Immunic receives notice of allowance for vidofludimus calcium patent

Immunic (IMUX) announced that it has received a notice of allowance from the United States Patent and Trademark Office for patent application 18/529,946, entitled, “Treatment of multiple sclerosis comprising DHODH inhibitors.” Specifically, the resulting patent covers dose strengths associated with lead asset, vidofludimus calcium, and other salt forms as well as free acid forms, at a daily dose of about 10 mg to 45 mg, for the treatment of progressive multiple sclerosis, including the sub-groups primary progressive multiple sclerosis and secondary progressive multiple sclerosis (SPMS). The patent is expected to provide protection into 2041, and potential Patent Term Extension may offer additional market exclusivity in the United States.